Faro AI Raises $37.3 Million in Series B Funding
Faro AI, a San Diego-based company specializing in AI platforms for clinical development, has successfully raised $37.3 million in a Series B funding round. This round was led by Ankona Capital, with participation from investors including General Catalyst, Merck Global Health Innovation Fund, Northpond Ventures, Polaris Partners, PTX Capital, S32, and Zetta.
Company Overview
Faro AI focuses on leveraging artificial intelligence to enhance the clinical development process. Their platform aims to streamline and optimize the various stages of clinical trials, potentially leading to more efficient and effective drug development.
Leadership and Vision
Scott Chetham, Co-Founder and CEO of Faro AI, has been at the forefront of driving the company's mission to innovate within the clinical development sector. "We are committed to transforming the way clinical trials are conducted," Chetham remarked, highlighting the potential impact of their AI solutions on the healthcare industry.
Strategic Use of Funds
While specific details on the allocation of the newly acquired funds were not disclosed, the investment is expected to support Faro AI's ongoing development and expansion efforts. This could include advancing their technology, expanding their team, or exploring new market opportunities.
Investor Confidence
The participation of prominent investors like General Catalyst and Merck Global Health Innovation Fund underscores the confidence in Faro AI's potential to make significant advancements in clinical development through AI technology.
With this substantial injection of capital, Faro AI is poised to further its mission of enhancing the efficiency and effectiveness of clinical trials, ultimately contributing to the broader healthcare landscape.